Understanding transcription and replications: We are interested in how loss of CDK12 leads to genomic tandem duplications in both prostate and ovarian cancer, and are interested in understanding the consequences of transcription:replication collisions. Through chemical and genetic CRISPR screening, we are also working to discover new synthetic lethalities in CDK12-deficient cancers, which we hope will lead to new investigator-initiated trials for this aggressive molecular subtype of cancer.

DLL3, PSMA, CDCP1 and more: We are interested in understanding the surface protein landscape of prostate cancer and developing new strategies to target old and new proteins, including bispecific T cell engagers (BiTEs), CAR T cells, antibody drug conjugates and radioimmunotherapies. We are also particularly interested in how resistance develops to these different therapies, and how to regulate antigen expression in tumor cells to enhance targeting.

NECTIN4, CDCP1, TROP2 and more: We are interested in understanding the surface protein landscape of bladder cancer and developing new strategies to target old and new proteins, including bispecific T cell engagers (BiTEs), CAR T cells, antibody drug conjugates and radioimmunotherapies. We are also particularly interested in how resistance develops to these different therapies, and how to regulate antigen expression in tumor cells to enhance targeting.